Semaglutide and Intestinal Iron Absorption

What Was Tested

In this not phased trial, researchers set out to test Semaglutide.

Semaglutide belongs to a group of long-acting glucagon-like peptide 1 receptor agonists (GLP-1).

Disorders in iron absorption have been linked to numerous medication, dietary, and nutrient interactions thus far.

The study aimed to determine whether there is an effect of concomitant parenteral administration of semaglutide and oral iron preparations on iron absorption in patients with type 2 diabetes (T2DM).

It had 1 arm (groups): T2DM subjects before and at week 10 of semaglutide therapy (experimental).

The registry classes the interventions as drug.

More on the Plan

Novel approaches to managing T2DM have been developed as a result of medical advancements.

Semaglutide, a long-acting GLP-1 RA, has a very high structural homology with endogenous GLP-1, high binding affinity to albumin, and resistance to degradation by the intestinal enzyme dipeptidyl peptidase-4.

Because of these characteristics and his extended half-life, it can be used once weekly.

Who Took Part

The registry lists 51 actual participants took part.

It was open to people of any sex aged from 45 years up to 65 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Ages between 45 and 65. Who are candidates for treatment intensification and beginning of parenterally administered semaglutide.

The full record lists 4 inclusion and 16 exclusion criteria; among the exclusions: hypersensitivity to glp-1 ras,; adequately controlled with current glucose-lowering medications,; already treated with glp-1 ra,.

How the Study Was Run

Design: single-group and open-label.

Nothing was hidden in this open-label Semaglutide study: the participants and staff both knew the treatment.

Everyone received the same intervention, so there was no separate comparison group inside the trial.

It started in 2023-11-01 with completion listed for 2024-04-01.

It ran at 1 site in Croatia.

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: General objective (time frame: 10 weeks).

It also tracked 1 secondary outcome, for example Specific objectives.

What This Means in Plain Language

Put simply, this is a not phased trial of Semaglutide in 51 people.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.